Johnson & Johnson (JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

克罗恩病，这个听起来似乎遥不可及的名字，却是许多人生活中的真实困扰。你是否听说过这种疾病，它不仅影响生活质量，还可能导致严重的身体不适？近年来，医药行业的发展给患者带来了希望，尤其是荃信生物-B（02509）近日获得的乌司奴单抗（Stelara®）对于克罗恩病的上市许可申请，无疑为患者的抗争铺就了一条新道路。 克罗恩病是一种慢性肠道炎症性疾病，患者通常经历腹痛、腹泻等令人难以忍受的症状。根据最新的 ...

2月12日，华东医药发布关于全资子公司收到药品注册受理通知书的公告。披露子公司杭州中美华东制药有限公司收到国家药品监督管理局（NMPA）签发的《受理通知书》，由中美华东申报的乌司奴单抗注射液（静脉输注）和乌司奴单抗注射液（研发代码：HDM3001-2/QX001S）用于克罗恩病的上市许可申请和补充申请获得受理。HDM3001（Q ...

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

HDM3001在克罗恩病这一新适应症的布局瞄准了持续增长的中国CD药物市场规模。公开资料显示，亚洲发病率虽然相比北美和西欧等发达国家较低，但呈明显的持续上升趋势。

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

2月12日晚，华东医药(000963)公告称，全资子公司杭州中美华东制药有限公司（下称“中美华东”）申报的乌司奴单抗注射液（静脉输注）和乌司奴单抗注射液（研发代码：HDM3001-2/QX001S）用于克罗恩病的上市许可申请和补充申请获得NMPA受理。这也意味着国产乌司奴单抗拓宽了适应症。此前，华东医药旗下乌司奴单抗注射液（赛乐 ...

Samsung Bioepis Co., Ltd. today announced that PYZCHIVA ® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...